Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul 19:12:922370.
doi: 10.3389/fonc.2022.922370. eCollection 2022.

Editorial: Real World Outcomes of Lymphoma From India

Lalit Kumar  1 , Naresh Kn  2 , Sumeet Gujral  3 , Padmaj Kulkarni  4 , Martin R Stockler  5 , Reena Nair  6
Affiliations
Editorial

Editorial: Real World Outcomes of Lymphoma From India

Lalit Kumar et al. Front Oncol. .
No abstract available

Keywords: Hodgkin lymphoma; biosimilars; diffuse large B cell lymphoma; real world evidence; real world outcomes; targeted therapies; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Real World Outcomes of Lymphomas in India

Similar articles

See all similar articles

Cited by

References

    1. Prashant M, Sathishkumar K, Chaturvedi M, Das P, Lakshminarayana Sudarshan K, Santhappan S, et al. . Cancer Statistics: Report From National Cancer Registry Programme, India. JCO Global Oncol (2020) 6:1063–75. doi: 10.1200/GO.20.00122 - DOI - PMC - PubMed
    1. Hyuna S, Feray J, Siegel RL, Laversanne M, Soerjomataram I, Jamal A, et al. . Global Cancer Statistics 2020: GLOBOCON Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/cacac.21660 - DOI - PubMed
    1. Ramesh N, Digumarti R, Nair R, Bhurani D, Raina V, Agarwal S, et al. . The Epidemiology of Lymphomas and Treatment Outcomes of Diffuse Large B Cell Lymphoma: Retrospective Analysis From India. Ind J Med Ped Oncol (2013) 34(4):299–304. doi: 10.4103/0971-5851.125250 - DOI - PMC - PubMed
    1. Reena N, Radhakrishnan V, Mallath MK. Global Haematology- Rituximab Biosimilars for B-Cell Lymphomas: A Decade of Real World Experience From India. thelancet.com/hematology (2021) 8:e548–9. doi: 10.1016/s2352-3026(21)00212 - DOI - PubMed
    1. Partha SR, Shiji J, Sadashiv K, Sadhana K, Pawaskar P, Gawande J, et al. . Comparison of Efficacy and Safety of Rituximab (Mabthera) and its Biosimilar (Reditux) in DLBCL Patients Treated With Chemo Immunotherapy: A Retrospective Analysis. Ind J Med Ped Oncol (2013) 34(4):292–298. doi: 10.4103/0971-5851.125248 - DOI - PMC - PubMed

Publication types

LinkOut - more resources